US-sourced Femara + Letrozole SIE

Phase 1Small molecule

US-sourced Femara + Letrozole SIE is one of 23 small molecule programs targeting Breast Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Breast CancerActive, not recruiting

Breast CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

2828 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Halaven

Eisai

Preclinical

38 2

Cymbalta

Alnylam Pharmaceuticals

Preclinical

3 3

MS Contin

Merck & Co.

Preclinical

2 4

Zinecard

CChildren's Oncology Group

Preclinical

2 5

Spravato

WWim Janssens

Preclinical

2 6

Effexor

WWyeth-Lederle Vaccines

Preclinical

2 7

Chirocaine

PPurdue Pharma LP

Preclinical

1 8

Nubain

AAultman Health Foundation

Preclinical

1 9

Aquasol E

NNational Eye Institute (NEI)

Preclinical

—10

Vfend

PPrism Pharmaceuticals

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1Not yet recruiting

Breast Cancer

NCT07401381

Clinical

Trials by Indication[1]

Breast Cancer1 trial

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

Not yet recruiting·RRovi Pharmaceuticals Laboratories·Phase 1·NCT07401381·120 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for US-sourced Femara + Letrozole SIE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — US-sourced Femara + Letrozole SIE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for US-sourced Femara + Letrozole SIE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Rovi Pharmaceuticals Laboratories company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: RRovi Pharmaceuticals Laboratories

US-sourced Femara + Letrozole SIE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News